Objective: This prospective study aimed to evaluate the effect of beinaglutide combined with metformin versus aspart 30 with metformin on metabolic profiles and antidrug antibodies (ADAs) in patients with type 2 diabetes (T2D).
Methods: A total of 134 eligible participants were randomly assigned to the test group and the control group. Patients in the test group were treated with beinaglutide and metformin, whereas patients in the control group were randomly treated with aspart 30 and metformin, with a follow-up period of 6 months. The metabolic profiles and ADAs over 6 months were evaluated.
Results: After 6 months, 101 (75.37%) patients completed the study. Compared with the control group, the beinaglutide group had significant reductions in 2-h postprandial blood glucose (2hBG) and low blood glucose index (LBGI). Glycated hemoglobin (HbA1c) decreased in both groups relative to baseline. In the test group, one had treatment-emergent beinaglutide ADAs. Significant reductions in triglycerides (TG), non-fasting TG, weight, waist circumference (WC), and body mass index (BMI) were observed. The values of insulin sensitivity index (HOMA-IR) were decreased to a statistically higher degree with beinaglutide treatment.
Conclusion: Beinaglutide reduces metabolic dysfunction, LBGI, and weight in patients of T2D with a low risk of ADAs. Beinaglutide may offer the potential for a disease-modifying intervention in cardiovascular disease (CVD).
Clinical Trial Registration: www.chictr.org.cn, identifier ChiCTR2200061003.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10731293 | PMC |
| http://dx.doi.org/10.3389/fendo.2023.1267503 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Severe palmoplantar keratoderma: a cutaneous complication from sub-optimally controlled type 2 diabetes.
Endocrinol Diabetes Metab Case Rep
January 2025
Summary: Palmoplantar keratoderma (PPK), characterised by excessive epidermal thickening of the skin on the palms and/or plantar surfaces of the feet, can be hereditary or acquired. Here, we report a case of a 53-year-old woman with a history of sub-optimally controlled diabetes mellitus presenting with fevers and decreased Glasgow Coma Scale (GCS) to a tertiary hospital. She was diagnosed with diabetic ketoacidosis (DKA), with blood glucose at 40 mmol/L and ketones at 7 mmol/L, in the setting of a methicillin-sensitive Staphylococcus aureus necrotising soft tissue back infection.
View Article and Find Full Text PDFGlycemia reduction in type 2 diabetes-Hypoglycemia outcomes: A randomized clinical trial.
PLoS One
November 2024
Department of Biostatistics and Bioinformatics, Milken Institute of Public Health, The Biostatistics Center, The George Washington University, Rockville, MD, United States of America.
Article Synopsis
- The study aimed to compare the risk of hypoglycemia among type 2 diabetes patients on metformin and adding one of four common therapies: glargine, glimepiride, liraglutide, or sitagliptin.
- The trial included 5,047 participants, assessing severe hypoglycemia events and symptoms over an average of 5 years, with a per-protocol analysis of 4,830 who completed follow-ups.
- Results showed that glimepiride had the highest incidence of severe hypoglycemia (1.3%), while liraglutide and sitagliptin had the lowest risks, indicating varying hypoglycemia likelihood based on the second medication added
The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
Diabetes Obes Metab
September 2024
Department of Endocrinology, The First Medical Centre, Chinese People's Liberation Army General Hospital, Beijing, China.
Aim: To compare the efficacy and safety of a fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with premixed insulin, insulin degludec plus insulin aspart (IDegAsp), in Chinese people with type 2 diabetes (T2D) suboptimally controlled with oral antidiabetic drug(s) (OADs).
Methods: In Soli-D, a 24-week, multicentre, open-label, study, insulin-naïve adults were randomized 1:1 to once-daily injections of iGlarLixi (n = 291) or IDegAsp (n = 291), with continued metformin ± sodium-glucose co-transporter-2 inhibitors. The primary endpoint was non-inferiority in HbA1c change from baseline to week 24.
Article Synopsis
- The study addresses the rising rates of gestational diabetes mellitus (GDM) and the need for effective management options, comparing the use of metformin and insulin for treatment.
- It emphasizes the importance of maintaining precise glucose control for maternal and fetal health, particularly through continuous glucose monitoring (CGM) that provides detailed glucose profiles and the time-in-range (TIR) metric.
- This randomized controlled trial evaluated TIR in 44 women with GDM, divided evenly into metformin and insulin groups, and found no significant differences in baseline characteristics between the two treatment options.
Improved pregnancy outcome in gestational diabetes mellitus patients treated with insulin aspart and metformin: a comparative study.
Am J Transl Res
April 2024
Department of Obstetrics, Ankang Central Hospital No. 85 Jinzhou South Road, Hanbin District, Ankang 725000, Shaanxi, China.
Article Synopsis
- The study aimed to evaluate how combining metformin with insulin aspart affects blood sugar control, kidney health, and pregnancy outcomes in patients with gestational diabetes mellitus (GDM).
- Researchers analyzed data from 140 GDM patients, dividing them into two groups: one treated with insulin aspart alone and the other with a combination of insulin aspart and metformin.
- Results showed that the combination treatment led to better blood glucose levels, lower kidney injury indicators, and fewer adverse pregnancy outcomes compared to insulin alone, suggesting it may be a beneficial approach for managing GDM.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!